^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Ezharmia (valemetostat) (EZH2 inhibitor, EZH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EZHARMIA® Approved in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Adult T-Cell Leukemia/ Lymphoma
Published date:
09/26/2022
Excerpt:
Daiichi Sankyo (TSE:5468) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved EZHARMIA® (valemetostat tosilate), a first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL).
